Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update

H Hans Messersmith (American Society of Clinical Oncology (ASCO), Alexandria, VA) A Andrew B. Lassman (Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, New York-Presbyterian, New York, NY) J Jaishri Blakeley (Johns Hopkins University School of Medicine, Baltimore, MD) N Na Tosha Gatson A Andreas F. Hottinger A Andrew Lassman N Nimish A. Mohile (Department of Neurology and Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY) J Jordan Morton D Douglas Ney (2University of Colorado, Department of Neurology, Aurora, United States) P Phioanh Leia Nghiemphu (Department of Neurology, University of California, Los Angeles, Los Angeles, CA) J James Perry (University of Maryland, Baltimore, MD, USA.) D David Schiff (31Department of Neurology, Division of Neuro-Oncology, University of Virginia, Charlottesville, VA) A Anne Shannon H Helen A. Shih (Department of Radiation Oncology, Mass General Brigham & Harvard Medical School, Boston, MA) R Roy Strowd (3Department of Cancer Medicine, Atrium Health Wake Forest University School of Medicine, Winston-Salem, United States) M Martin van den Bent M Mateo Ziu

Abstract

ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual . The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only).

Article Details

Volume / Issue Vol. 43, Issue 18
Published June 20, 2025
Pages 2129-2133
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (17)

H

Hans Messersmith

American Society of Clinical Oncology (ASCO), Alexandria, VA

A

Andrew B. Lassman

Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, New York-Presbyterian, New York, NY

J

Jaishri Blakeley

Johns Hopkins University School of Medicine, Baltimore, MD

N

Na Tosha Gatson

A

Andreas F. Hottinger

A

Andrew Lassman

N

Nimish A. Mohile

Department of Neurology and Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY

J

Jordan Morton

D

Douglas Ney

2University of Colorado, Department of Neurology, Aurora, United States

P

Phioanh Leia Nghiemphu

Department of Neurology, University of California, Los Angeles, Los Angeles, CA

J

James Perry

University of Maryland, Baltimore, MD, USA.

D

David Schiff

31Department of Neurology, Division of Neuro-Oncology, University of Virginia, Charlottesville, VA

A

Anne Shannon

H

Helen A. Shih

Department of Radiation Oncology, Mass General Brigham & Harvard Medical School, Boston, MA

R

Roy Strowd

3Department of Cancer Medicine, Atrium Health Wake Forest University School of Medicine, Winston-Salem, United States

M

Martin van den Bent

M

Mateo Ziu